AcuCort AB (Spotlight Stock Market: ACUC) today announced that the Japan Patent Office (JPO) has granted a patent for the company’s drug ISICORT®. The positive decision means a patent protection for ISICORT® in Japan until the year 2035.
ISICORT® is a thin, fast-dissolving and user-friendly oral film for the treatment of acute and severe allergic reactions, for croup in children, chemotherapy-induced nausea and vomiting (CINV) as well as for COVID-19 in patients who need supplemental oxygen treatment. The fast-dissolving oral film contains the glucocorticoid dexamethasone which is a well-known, often used and well-documented anti-inflammatory substance. In October 2020, ISICORT® received market approval by the Swedish Medical Products Agency.
AcuCort has an active patent strategy that covers all major geographic markets, including Japan. The fact that ISICORT® now also has patent protection in Japan means that AcuCort’s drug has patent protection in a total of 32 countries at present.
“We are very pleased that AcuCort has been granted a patent protection for ISICORT® by the Japanese Patent Office. Japan is one of the world’s largest pharmaceutical markets and is a major potential market for ISICORT®. Furthermore, our partner dialogues, preparations for commercialization and the work to achieve market approval in more markets continues, says Jonas Jönmark, CEO of AcuCort AB.
The information was submitted for publication, through the agency of the contact person below, on March 30, 2021.
For more information, please contact
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
About AcuCort AB (publ)
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). In February 2021, the Swedish Medical Products Agency (MPA) granted ISICORT® the indication – treatment of COVID-19 in patients who need supplemental oxygen treatment. The bioequivalence study that forms the basis of the application for market approval in Europe was carried out with positive results and the Swedish national application was approved by the Swedish MPA in October 2020. Altogether, this strengthens the company’s assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.com.